1832 Asset Management’s Abiomed Inc ABMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-28,000
Closed -$4.92M 762
2019
Q3
$4.92M Buy
+28,000
New +$6.05M 0.02% 293
2019
Q1
Sell
-333,300
Closed -$106M 728
2018
Q4
$106M Buy
333,300
+141,927
+74% +$49.3M 0.42% 64
2018
Q3
$84.3M Sell
191,373
-10,427
-5% -$4.11M 0.27% 89
2018
Q2
$80.5M Sell
201,800
-170,900
-46% -$61.9M 0.27% 91
2018
Q1
$106M Sell
372,700
-2,200
-0.6% -$558K 0.39% 67
2017
Q4
$68.4M Buy
374,900
+21,100
+6% +$3.94M 0.22% 98
2017
Q3
$56.7M Sell
353,800
-10,000
-3% -$1.51M 0.2% 99
2017
Q2
$51M Buy
363,800
+19,000
+6% +$2.55M 0.23% 101
2017
Q1
$42.4M Sell
344,800
-1,294,100
-79% -$150M 0.15% 136
2016
Q4
$194M Buy
1,638,900
+514,900
+46% +$59.6M 0.33% 79
2016
Q3
$141M Buy
1,124,000
+1,100
+0.1% +$132K 0.53% 50
2016
Q2
$122M Buy
1,122,900
+322,600
+40% +$32.1M 0.47% 55
2016
Q1
$122M Buy
+800,300
New +$67.6M 0.3% 85
2015
Q4
Sell
-1,140,300
Closed -$104M 723
2015
Q3
$104M Buy
1,140,300
+245,800
+27% +$21.7M 0.43% 64
2015
Q2
$57.4M Buy
894,500
+879,000
+5,671% +$58.4M 0.19% 118
2015
Q1
$1.11M Buy
+15,500
New +$841K ﹤0.01% 405

Other funds holding ABMD

1832 Asset Management's ABMD Position: Q4 2019 in Review

1832 Asset Management sold out of Abiomed Inc (ABMD) in Q4 2019, closing a stake of 28,000 shares — an estimated $4.92M sold.

1832 Asset Management first reported a position in ABMD in Q1 2015 and held it in 16 quarters. The position peaked at $194M in Q4 2016. 465 funds tracked by Wall St. Rank hold ABMD as of Q4 2019.

  • 1832 Asset Management reported no remaining Abiomed Inc position as of Q4 2019 after selling out during the quarter.
  • 1832 Asset Management sold 28,000 Abiomed Inc shares in Q4 2019, an estimated $4.92M.
  • 1832 Asset Management first reported a position in Abiomed Inc in Q1 2015 and held it in 16 quarters.
  • 1832 Asset Management's Abiomed Inc position peaked at $194M in Q4 2016.
  • 465 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2019.

Based on 1832 Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.